Linagliptin 5 mg and Dapagliflozin 10 mg, marketed under the name LINALIGLIP DAPA 5-10, is a combination medication used to manage type 2 diabetes. This medication combines the benefits of Linagliptin, a DPP-4 inhibitor, and Dapagliflozin, an SGLT2 inhibitor, to effectively control blood glucose levels and improve overall glycemic management.

How Does It Work?

Linagliptin

• Inhibits the DPP-4 enzyme
• Increases incretin hormone levels
• Enhances insulin secretion
• Decreases glucagon levels

Dapagliflozin

• Inhibits SGLT2 in kidneys
• Reduces glucose reabsorption
• Increases glucose excretion through urine
• Lowers blood glucose levels

Uses of LINALIGLIP DAPA 5-10

• Manages type 2 diabetes
• Improves glycemic control
• Reduces the risk of cardiovascular events

What is LINALIGLIP DAPA 5-10?

LINALIGLIP DAPA 5-10 is a dual-action antidiabetic medication that combines Linagliptin and Dapagliflozin. It is designed to enhance insulin sensitivity, reduce hepatic glucose production, and promote glucose excretion through the urine, thus maintaining optimal blood sugar levels.

Side Effects

• Hypoglycemia
• Urinary tract infections
• Nasopharyngitis
• Diarrhea
• Increased urination
• Back pain

Safety Information

• Monitor renal function regularly
• Avoid in patients with severe renal impairment
• Use caution in elderly patients
• Ensure adequate hydration to prevent dehydration
• Consult a healthcare provider before use during pregnancy or lactation

If You Need More Information About  LINALIGLIP DAPA 5-10  Click here